Novo Nordisk and Vivtex collaborate to develop oral medicines
Novo Nordisk and Vivtex have entered right into a partnership centered on creating next-generation oral biologic therapies for the remedy of weight problems, diabetes and associated comorbidities.
Vivtex will license sure oral drug supply applied sciences to Novo Nordisk and is predicted to obtain analysis funding, upfront and milestone funds of as much as $2.1 billion, together with incremental royalties on future product gross sales.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The partnership goals to allow oral administration of organic drug candidates which might be historically injected as a result of poor absorption within the gastrointestinal tract.
The aim is to establish next-generation oral therapies by bringing collectively Novo Nordisk’s expertise in peptide and protein therapies with Vivtex’s gastrointestinal screening and formulation platform.
Novo Nordisk’s senior vice chairman of therapeutic discoveries, Brian Vandahl, mentioned: “Novo Nordisk has been on the forefront of innovation in protein and peptide engineering for many years, not least within the discipline of oral peptide formulation. We launched the first-ever oral biologic greater than 5 years in the past and just lately launched the world’s first oral biologic for weight problems.
“We proceed to push the boundaries of science by each inner and exterior innovation to satisfy our mission of treating thousands and thousands extra individuals with weight problems and diabetes and their related comorbidities.”
Vivtex CEO and co-founder Thomas von Erlach mentioned: “Oralizing biologics has been probably the most tough challenges in drug supply. Vivtex was based to systematically resolve this drawback by integrating high-throughput experiments with computational and AI-based analytics.
“By working with Novo Nordisk, we are able to apply our platform to essential areas of metabolic illness, with the goal of enabling oral therapies that will in any other case require injection.”
Vivtex’s platform integrates drug supply applied sciences, gastrointestinal screening assays, AI instruments and computational simulation to optimize the oral supply of biologic medication.
The system is designed for top oral bioavailability and constant efficiency in people.
Following the analysis and formulation choice phases, Novo Nordisk will oversee the worldwide growth, regulatory actions, manufacturing and commercialization of any profitable merchandise.
Final month, the corporate initiated a brand new section in its ongoing collaboration with Side Biosystems, which focuses on healing mobile medicines for the remedy of diabetes.
